

## DAFTAR PUSTAKA

1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. *Int J Womens Health*. 2019;11:287–99.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.
3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. *Best Pract Res Clin Obstet Gynaecol*. 2017;41:3–14.
4. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(4):284–96.
5. American Cancer Society. *Cancer Facts & Figures 2018*, Estados Unidos. 2018;6.
6. World Health Organization. *Cancer Country Profiles: Indonesia*. *Cancer Ctry Profiles*. 2014;22–3.
7. Dhitayoni AI, Gede NI. Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar-Bali Periode Juli 2013-Juni 2014. *E-Jurnal Medika* . 2017;17(3):23–32.
8. Lheureux S, Braunstein M. Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine. *CA Cancer J Clin*. 2019;280–304.
9. Kurman RJ, Shih IM. The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory. *Am J Surg Pathol*. 2011;34(3):433–443.
10. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet*. 2019;393(10177):1240–53.
11. Septaprima M. Hubungan Skor Risk Malignancy Index Dengan Subtipe Kanker Epitel Ovarium Di Rsup Dr. M. Djamil Padang. Padang : Fakultas Kedokteran Universitas Andalas (Skripsi);2019.
12. Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. *Clin Chim Acta*. 2013;415:341–5.
13. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. *J Exp Clin Cancer Res*. 2012;31(1):14.
14. Gabra H. Epithelial Ovarian Cancer. *Dewhurst's Textb Obstet Gynaecol Seventh Ed*. 2008;625–35.
15. Chandra A, Pius C, Nabeel M, Nair M, Vishwanata JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. *Journal Cancer Medicine*. 2019;8(16):7018-7031.

16. Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. *Lancet*. 2019;394(10214):2084–95.
17. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. *Ther Adv Med Oncol*. 2014;6(5):229–39.
18. Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. *Ann Oncol*. 2012;23(SUPPL. 10).
19. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. *Crit Rev Oncol Hematol*. 2014;89(2):207–16.
20. Snell RS. *Anatomi Klinis Berdasarkan Sistem*. 2006.
21. Eroschenko VP. *diFiore's Atlas of Histology with Functional Correlations 11<sup>th</sup> Edition*. 2011.
22. Junqueira. *Basic Histology Text and Atlas 14th Edition*. 2007.
23. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med*. 2017;14(1):9–32.
24. Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One*. 2018;13(10):1–10.
25. Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. *BMC Cancer*. 2018;18(1):1–18.
26. Desai A. Epithelial ovarian cancer: An overview. *World J Transl Med*. 2014;3(1):1.
27. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. *Int J Cancer*. 2003;104(2):228–32.
28. Karst AM, Drapkin R. Ovarian Cancer Pathogenesis: A Model in Evolution. *J Oncol*. 2010;2010:1–13.
29. Choi JH, Wong AST, Huang HF, Leung PCK. Gonadotropins and ovarian cancer. *Endocr Rev*. 2007;28(4):440–61.
30. Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. *Endocr Relat Cancer*. 2015;22(6):R339–93.
31. Rasmussen CB, Kjaer SK, Albieri V, Bandera E V, Doherty JA, Høgdall E, et al. Systematic Reviews and Meta- and Pooled Analyses Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors : A Pooled Analysis of 13 Case-Control Studies. 2017;185(1):8–20.
32. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen

- S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J Gynecol Oncol*. 2012;23(4):265–73.
33. Macciò A, Madeddu C. Inflammation and ovarian cancer. *Cytokine*. 2012;58(2):133–47.
  34. Christina IM, Philipp F, Hauptmann S, Sehouli J, Mucinous EÁ, Clear Á. The new WHO classification of ovarian , fallopian tube , and primary peritoneal cancer and its clinical implications. *Arch Gynecol Obstet*. 2016;293(4):695–700.
  35. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and type II. *Biomed Res Int*. 2014;2014.
  36. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and Management of Ovarian Cancer. *American Family Physician*. 2016;93(11).
  37. Prat J, Belhadj H, Berek J, Bermudez A, Bhatla N, Cain J, et al. Figo's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. *J Gynecol Oncol*. 2015;26(2):87–9.
  38. American Cancer Society. *Cancer Facts & Figures 2018, Special Section: Ovarian Cancer*. 2018;35.
  39. Obstetrics D, R EJ, Ronald S, Beth Y, Arthur F, By DND, et al. *Danforth ' s Obstetrics and Gynecology 9<sup>th</sup> Edition*. 2003.
  40. Made N, Suastari P. Pemeriksaan Radiologi untuk Deteksi Kanker Ovarium. *CDK Journal*. 2018;45(4):298–302.
  41. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24(SUPPL.6):vi24–32.
  42. Ligament B. Special Section : Ovarian Cancer. *Am Cancer Soc*. 2018;45(2):28–43.
  43. Van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. *Endocr Relat Cancer*. 2018;25(5):R303–18.
  44. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. *J Exp Clin Cancer Res*. 2012;31(1):1–8.
  45. Damia G, Brogini M. Platinum resistance in ovarian cancer: Role of DNA repair. *Cancers (Basel)*. 2019;11(1):1–15.
  46. Brown J, Frumovitz M. Mucinous tumors of the ovary: Current thoughts on diagnosis and management. *Curr Oncol Rep*. 2014;16(6).
  47. Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. *Eur J Cancer, Suppl*. 2014;12(2):7–12.
  48. Imanuel T.Gea, MAria F. Loho FW wagey. Gambaran jenis kanker ovarium di RSUP Prof . Dr . R . D . Kandou Manado. *E-Clinic*. 2016;4:2–6.
  49. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium

Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *J Kesehat Andalas*. 2014;3(1):54–7.

50. Novia D. Analisis Faktor Yang Berhubungan Dengan Kejadian Kanker Ovarium Tipe Epitel Di Rsup Dr. M. Djamil Padang Tahun 2017 - 2018. Padang : Fakultas Kedokteran Universitas Andalas (Skripsi);2020.
51. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. *Eur J Cancer*. 2013;49(2):520–30.
52. Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: A retrospective study. *Anticancer Res*. 2005;25(5):3501–5.
53. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. *Lancet Oncol*. 2011;12(12):1169–74.

